Biotechnology

The spatial biology leader will unveil its roadmap at AGBT 2026, targeting the next frontiers of drug discovery with 3D imaging and human-relevant models.

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

With new kits for complex cell models, Atrandi's semi-permeable capsules challenge market leaders by enabling multi-step workflows previously out of reach.

With two strategic hires from TriNetX and Canon Medical, Avandra signals an aggressive push to unlock siloed medical imaging data for research and AI.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

With a pivotal data release on the horizon, Passage Bio heads to two major conferences. Can its dementia gene therapy program win over Wall Street?

New data shows an AI-driven approach is enrolling IBD patients 3.4x faster, promising to accelerate the delivery of novel therapies to those in need.

With BRINSUPRI revenues set to hit $1B, Insmed is pouring cash into a high-stakes pipeline. Can it outrun its massive burn rate to deliver the next breakthrough?

Early data on YOLT-202 shows it can safely restore normal protein levels in patients with Alpha-1 Antitrypsin Deficiency, a major step toward a cure.

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

Early data reveals a novel immunotherapy, STC-1010, may activate the immune system against a common, treatment-resistant form of colorectal cancer.

As argenx prepares its full-year 2025 update, investors are watching if the VYVGART sales boom can fund a pipeline aimed at dominating autoimmune care.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

With $3.7M in new capital, Sift Biosciences is developing a novel immunotherapy to awaken the body's memory T cells against hard-to-treat diseases.

Johnson & Johnson is investing over $1 billion in a new Pennsylvania cell therapy hub, promising revolutionary treatments and thousands of new jobs.

Flatiron Health launches a first-of-its-kind AI platform, merging data from 400,000 patients to revolutionize prostate cancer research and treatment.